Updated results from the multicenter phase II study of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Zhou, F. [1 ]
Wang, W. [2 ]
Xia, L. [2 ]
Dai, J. [2 ]
Wu, H. [1 ]
Yang, L. [1 ]
Gong, J. [3 ]
Chen, X. [4 ]
Xiong, Z. [5 ]
Liang, X. [6 ]
机构：
[1] Wuhan Univ, Zhongnan Hosp, Radiochemotherapy Dept, Hepatobiliary Pancreas Abdominal Tumor, Wuhan, Peoples R China
[2] Wuhan Univ, Zhongnan Hosp, Radiochemotherapy Dept, Gastrointestinal Tumor, Wuhan, Peoples R China
[3] Huangshi Cent Hosp, Med Oncol, Huangshi, Hubei, Peoples R China
[4] Henan Canc Hosp, Med Oncol, Zhengzhou, Peoples R China
[5] HuBei Canc Hosp, Gastrointestinal Surg, Wuhan, Peoples R China
[6] HuBei Canc Hosp, Dept Med, Wuhan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1803
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
612P
引用
收藏
页码：S439 / S439
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC).
    Zhou, Fuxiang
    Wang Wen-bo
    Xia, Ling
    Dai, Jing
    Wu, Han
    Yang, Lei
    Xiong, Zhiguo
    Gong, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 152 - 152
  • [2] A Phase II Clinical Study of mFOLFOX6 Plus Bevacizumab as First-line Therapy for Japanese Advanced/Recurrent Colorectal Cancer Patients
    Nishina, Tomohiro
    Takano, Yoshinao
    Denda, Tadamichi
    Yasui, Hisateru
    Takeda, Koji
    Ura, Takashi
    Esaki, Taito
    Okuyama, Yusuke
    Kondo, Ken
    Takahashi, Yasuo
    Sugiyama, Yasuyuki
    Muro, Kei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (11) : 1080 - 1086
  • [3] A randomized study of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 as first-line treatment for unresectable metastatic colorectal cancer
    Belhadef, S.
    Arab, A.
    Belmadi, M.
    Beninal, M.
    Bacha, N.
    Abdallah, R.
    Mechta, K.
    Dahmane, A.
    Mahfouf, H.
    Oukkal, M.
    Bouzid, K.
    Faraqun, S.
    Bentabak, K.
    Younes, S. Ait
    ANNALS OF ONCOLOGY, 2020, 31 : S92 - S92
  • [4] Fruquintinib combined with FOLFIRI/mFOLFOX6 as second-line treatment in patients with RAS-mutant metastatic colorectal cancer (mCRC): A multicenter, open-label, phase II study.
    Xu, Yun
    Wu, Yuchen
    Dai, Yuedi
    Ji, Xiaopin
    Cui, Zhe
    Zhu, Xiaodong
    Xu, Ye
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 151 - 151
  • [5] A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients
    Van Cutsem, E.
    Prenen, H.
    D'Haens, G.
    Bennouna, J.
    Carrato, A.
    Ducreux, M.
    Bouche, O.
    Sobrero, A.
    Latini, L.
    Staines, H.
    Oum'Hamed, Z.
    Dressler, H.
    Studeny, M.
    Capdevila, J.
    ANNALS OF ONCOLOGY, 2015, 26 (10) : 2085 - 2091
  • [6] UPDATED PHASE II STUDY RESULTS OF CAPECITABINE (X) plus IRINOTECAN (I) plus BEVACIZUMAB (A) AS FIRST-LINE THERAPY FOR METASTATIC COLORECTAL CANCER (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    ANNALS OF ONCOLOGY, 2008, 19 : 130 - 130
  • [7] Updated phase II study results of capecitabine (X) plus irinotecan (I) plus bevacizumab (A) as first-line therapy for metastatic colorectal cancer (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Smoljanovic, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] UPDATED PHASE II STUDY RESULTS OF CAPECITABINE (X) plus IRINOTECAN (I) plus BEVACIZUMAB (A) AS FIRST-LINE THERAPY FOR METASTATIC COLORECTAL CANCER (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Smoljanovic, V
    ANNALS OF ONCOLOGY, 2009, 20 : 76 - 76
  • [9] A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer
    Kearney, Matthew R.
    Chen, Emerson Y.
    Vaccaro, Gina M.
    Strother, John
    Burt, Andrea
    Todd, Kendra
    Donovan, Jeff
    Kampa-Schittenhelm, Kerstin M.
    Lopez, Charles D.
    ANTICANCER RESEARCH, 2019, 39 (01) : 245 - 252
  • [10] Phase Ib Study of Drozitumab Combined with First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer
    Lima, Caio M. Rocha
    Bayraktar, Soley
    Flores, Aurea M.
    MacIntyre, Jessica
    Montero, Alberto
    Baranda, Joaquina C.
    Wallmark, John
    Portera, Chia
    Raja, Rajiv
    Stern, Howard
    Royer-Joo, Stephanie
    Amler, Lukas C.
    CANCER INVESTIGATION, 2012, 30 (10) : 727 - 731
12345